Heard in the Myriad Genetics (MYGN +5.5%) Supreme Court case: Justice Scalia asks why a company...


Heard in the Myriad Genetics (MYGN +5.5%) Supreme Court case: Justice Scalia asks why a company would incur huge development costs if it is prohibited from patenting discoveries; Sotomayor, Breyer, and Kennedy ask if middle ground is possible wherein patents are allowed on cDNA but not an "isolated DNA"; Myriad's lawyers asked to consider if middle ground would grant "sufficient protection for innovation and research." (Bloomberg)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs